Neuroprotective Effect of Withaferin Derivatives toward MPP+ and 6‑OHDA Toxicity to Dopaminergic Neurons
Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydr...
Saved in:
Published in | ACS chemical neuroscience Vol. 16; no. 5; pp. 802 - 817 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
05.03.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 1948-7193 1948-7193 |
DOI | 10.1021/acschemneuro.4c00655 |
Cover
Abstract | Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans. |
---|---|
AbstractList | Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP
) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms.
(L.)
, commonly known as
, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound
(
), a steroid lactone from the
group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of
and two of its molecular derivatives,
and
, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that
and its two derivatives,
and
, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP
and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode
. Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans. Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans.Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be phenotypically reproduced in various experimental models through the administration of two neurotoxins: N-methyl-4-phenylpyridinium (MPP+) and 6-hydroxydopamine (6-OHDA). The mechanisms underlying the cell death processes induced by these toxins remain a subject of debate. In this context, studies suggest that oxidative-stress-related processes may contribute to the dysfunction and death of dopaminergic neurons. Therefore, investigating pharmacological compounds that can counteract these processes remains crucial for developing therapeutic strategies targeting these neuropathological mechanisms. Withania somnifera (L.) Dunal, commonly known as ashwagandha, is a plant whose roots are used in Ayurvedic medicine to treat various ailments, including those affecting the central nervous system. The active compound Withaferin-A (WFA), a steroid lactone from the withanolide group, is reported to possess antioxidant properties. In this study, we explored the potential neuroprotective effects of WFA and two of its molecular derivatives, cr-591 and cr-777, which contain, respectively, an additional cysteine or glutathione chemical group, known for their antiradical properties. We demonstrated that WFA and its two derivatives, cr-591 and cr-777, protect the integrity and function of dopaminergic neurons exposed to the neurotoxins MPP+ and 6-OHDA both in vitro, using primary mesencephalic neuron cultures from rodents, and in vivo, using the nematode Caenorhabditis elegans. |
Author | Normant, Sébastien Laserre, Louise Le Goff, Géraldine Parrales, Valeria Callizot, Noelle Da Costa Noble, Christian Bizat, Nicolas Arcile, Guillaume Rabhi, Chérif Haïk, Stéphane Ouazzani, Jamal |
AuthorAffiliation | AP-HP, Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob Neuro-Sys Faculté de Pharmacie de Paris Paris Brain Institute, Inserm U1127, CNRS Sorbonne University, Hospital Pitié-Salpêtrière Paris University University Hospital Pitié-Salpêtrière Laboratoire Ethnodyne |
AuthorAffiliation_xml | – name: University Hospital Pitié-Salpêtrière – name: AP-HP, Cellule Nationale de Référence des Maladies de Creutzfeldt-Jakob – name: Laboratoire Ethnodyne – name: Paris Brain Institute, Inserm U1127, CNRS Sorbonne University, Hospital Pitié-Salpêtrière – name: Faculté de Pharmacie de Paris – name: Neuro-Sys – name: Paris University |
Author_xml | – sequence: 1 givenname: Valeria surname: Parrales fullname: Parrales, Valeria organization: Laboratoire Ethnodyne – sequence: 2 givenname: Guillaume surname: Arcile fullname: Arcile, Guillaume – sequence: 3 givenname: Louise surname: Laserre fullname: Laserre, Louise organization: Paris Brain Institute, Inserm U1127, CNRS Sorbonne University, Hospital Pitié-Salpêtrière – sequence: 4 givenname: Sébastien surname: Normant fullname: Normant, Sébastien organization: Laboratoire Ethnodyne – sequence: 5 givenname: Géraldine surname: Le Goff fullname: Le Goff, Géraldine – sequence: 6 givenname: Christian surname: Da Costa Noble fullname: Da Costa Noble, Christian organization: Laboratoire Ethnodyne – sequence: 7 givenname: Jamal orcidid: 0000-0003-4483-6638 surname: Ouazzani fullname: Ouazzani, Jamal – sequence: 8 givenname: Noelle surname: Callizot fullname: Callizot, Noelle organization: Neuro-Sys – sequence: 9 givenname: Stéphane surname: Haïk fullname: Haïk, Stéphane organization: University Hospital Pitié-Salpêtrière – sequence: 10 givenname: Chérif surname: Rabhi fullname: Rabhi, Chérif email: c.rabhi@ethnodyne.com organization: Laboratoire Ethnodyne – sequence: 11 givenname: Nicolas orcidid: 0000-0001-9643-4417 surname: Bizat fullname: Bizat, Nicolas email: nicolas.bizat@icm-institute.org organization: Paris University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39946298$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc9OGzEQxq0KVCD0DarKx0oowd5d25kjIrRU4t8BxHHl9Y6Lo6yd2rsBbn2FviJPgtOkFScuMyPN7xvr83dAdnzwSMhnziacFfxYm2QesPM4xDCpDGNSiA9kn0M1HSsO5c6beY8cpDTPCLCp_Ej2SoBKFjDdJ_OrtX4ZQ4-mdyukZ9bmiQZL713_oC1G5-ks15Ve7xPtw6OOLb28uTmi2rdUvvz-c30-O6G34ckZ1z9ngs7CUnfOY_zpDP37hE-HZNfqRcJP2z4id9_Obk_PxxfX33-cnlyMdQGqH1tEpTSXuYNqZNsY5A0UFQAThVClqkoFwIWVANAI27bZzLRoBAojWCHLEfm6uZtd_Row9XXnksHFQnsMQ6pLLqWSpYAio1-26NB02NbL6Dodn-t__5OBagOYGFKKaP8jnNXrGOq3MdTbGLKMbWR5W8_DEH02_L7kFc1-j9c |
Cites_doi | 10.1021/acschemneuro.2c00356 10.1016/j.jchemneu.2020.101752 10.1055/a-1349-3870 10.3390/ijms22168689 10.1002/syn.890150107 10.1038/349414a0 10.3390/ph16020160 10.1093/brain/awab152 10.1016/j.jep.2020.112769 10.1016/j.bcp.2012.08.027 10.2174/0118715249264078231214074107 10.1098/rstb.1986.0056 10.1073/pnas.042497999 10.1016/S0197-0186(96)00025-3 10.1046/j.1471-4159.2002.01000.x 10.1126/science.282.5396.2028 10.1002/ps.3583 10.1016/j.addr.2013.12.001 10.1016/j.steroids.2023.109246 10.1038/35072550 10.1016/j.biopha.2018.06.002 10.1152/physrev.00026.2013 10.3390/cells12091336 10.1002/mnfr.201400014 10.1007/s10495-008-0273-y 10.1016/j.ejmech.2017.09.004 10.3389/fphar.2023.1049334 10.3390/molecules14072373 10.1002/ptr.874 10.1016/0304-3940(88)90705-7 10.3389/fpsyg.2014.01093 10.1016/S0022-3565(25)27139-7 10.1155/2014/768594 10.1016/j.nbd.2021.105256 10.1021/jm00027a021 10.1523/JNEUROSCI.0374-11.2011 10.1038/cr.2008.279 10.1111/bcpt.14011 10.3389/fnins.2020.00303 10.1038/sj.cdd.4402002 10.1248/cpb.50.760 10.1016/j.ejphar.2024.176819 10.1038/nchembio755 10.1248/bpb.b14-00022 10.1046/j.1471-4159.2001.00183.x 10.1207/S15327914NC421_12 10.1007/s10571-006-9003-6 10.1111/j.1471-4159.1992.tb10080.x 10.1016/S0022-3565(25)26555-7 10.3791/59243 10.1016/S0166-4328(89)80121-4 10.3390/ijms25010443 10.1056/nejm198308043090511 10.1016/j.jep.2009.08.003 10.1086/302486 10.1371/journal.pone.0238528 10.1111/j.1476-5381.2010.00725.x 10.1385/JMN/31:02:127 10.1155/2021/9912436 10.1371/journal.pgen.1007106 10.1016/j.exger.2019.110653 10.1523/JNEUROSCI.2992-07.2007 10.1016/0006-291X(86)91211-8 10.1016/S0072-9752(07)83027-2 10.1096/fj.07-095398 10.1038/cdd.2017.186 10.1016/j.steroids.2011.05.012 10.1074/jbc.C500288200 10.1097/00001756-200006260-00035 10.1101/sqb.1983.048.01.049 10.3233/JPD-171258 10.3390/biomedicines11092488 10.18632/oncotarget.20497 10.3390/molecules24244599 10.1016/j.neuint.2016.01.008 10.1016/0024-3205(87)90299-2 10.1016/j.steroids.2022.109172 10.4103/1673-5374.290894 10.1124/mol.106.030015 10.3389/fgene.2012.00048 10.1016/0304-3940(87)90366-1 10.1016/S0378-8741(97)00151-7 10.1016/j.mcn.2016.06.001 10.2478/s11658-007-0015-0 10.1191/0960327105ht509oa 10.4103/0250-474X.95656 10.1159/000080983 10.1007/s11064-014-1443-7 10.1007/BF01271538 10.1016/j.chemosphere.2024.143303 10.3390/ijms22062929 10.1038/nrd1330 10.1016/0012-1606(77)90158-0 10.1016/j.ddtec.2012.02.002 10.1016/S0091-679X(08)61399-0 10.1093/brain/114.5.2283 10.1016/S0301-0082(01)00003-X |
ContentType | Journal Article |
Copyright | 2025 American Chemical Society |
Copyright_xml | – notice: 2025 American Chemical Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1021/acschemneuro.4c00655 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1948-7193 |
EndPage | 817 |
ExternalDocumentID | 39946298 10_1021_acschemneuro_4c00655 a566519098 |
Genre | Journal Article |
GroupedDBID | --- 53G 55A 5VS 6J9 7~N AABXI AAKDD ABJNI ABMVS ABQRX ABUCX ACGFO ACGFS ACS ADBBV ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH BAWUL CUPRZ EBS ED~ F5P GGK GNL GX1 IH9 JG~ OK1 RNS ROL RPM UI2 VF5 VG9 W1F AAYXX ABBLG ABLBI CITATION CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-a297t-fee77a16fee97b6dbce1b9249905257374379915f6999b5fdd99482b5e5c50263 |
IEDL.DBID | ACS |
ISSN | 1948-7193 |
IngestDate | Thu Jul 10 21:56:05 EDT 2025 Fri May 09 01:30:37 EDT 2025 Wed Oct 01 06:50:38 EDT 2025 Thu Mar 06 04:56:18 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Withaferin A C. elegans cr-777 drug discovery cr-591 neurodegeneration 6-OHDA MPP Parkinson’s disease |
Language | English |
License | https://doi.org/10.15223/policy-029 https://doi.org/10.15223/policy-037 https://doi.org/10.15223/policy-045 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a297t-fee77a16fee97b6dbce1b9249905257374379915f6999b5fdd99482b5e5c50263 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4483-6638 0000-0001-9643-4417 |
PMID | 39946298 |
PQID | 3166763592 |
PQPubID | 23479 |
PageCount | 16 |
ParticipantIDs | proquest_miscellaneous_3166763592 pubmed_primary_39946298 crossref_primary_10_1021_acschemneuro_4c00655 acs_journals_10_1021_acschemneuro_4c00655 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-03-05 |
PublicationDateYYYYMMDD | 2025-03-05 |
PublicationDate_xml | – month: 03 year: 2025 text: 2025-03-05 day: 05 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | ACS chemical neuroscience |
PublicationTitleAlternate | ACS Chem. Neurosci |
PublicationYear | 2025 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref3/cit3 ref81/cit81 ref16/cit16 ref52/cit52 ref23/cit23 ref2/cit2 ref77/cit77 ref20/cit20 ref48/cit48 ref74/cit74 ref10/cit10 ref35/cit35 ref89/cit89 ref19/cit19 ref93/cit93 ref42/cit42 ref96/cit96 ref13/cit13 ref61/cit61 ref67/cit67 ref38/cit38 ref90/cit90 ref64/cit64 ref54/cit54 ref6/cit6 ref18/cit18 Porter C. C. (ref45/cit45) 1965; 150 ref65/cit65 ref97/cit97 ref11/cit11 ref29/cit29 ref76/cit76 ref86/cit86 ref32/cit32 ref39/cit39 ref5/cit5 Bhattacharya S. K. (ref71/cit71) 1997; 35 ref43/cit43 ref80/cit80 ref28/cit28 ref91/cit91 ref55/cit55 ref12/cit12 ref66/cit66 ref22/cit22 ref33/cit33 ref87/cit87 ref44/cit44 ref70/cit70 ref98/cit98 ref9/cit9 ref27/cit27 ref63/cit63 ref56/cit56 Porter C. C. (ref46/cit46) 1963; 140 ref92/cit92 ref8/cit8 ref31/cit31 ref59/cit59 ref85/cit85 ref34/cit34 ref37/cit37 ref60/cit60 ref88/cit88 ref17/cit17 ref82/cit82 ref53/cit53 ref21/cit21 ref49/cit49 ref75/cit75 ref24/cit24 ref50/cit50 ref78/cit78 ref36/cit36 ref83/cit83 ref79/cit79 ref25/cit25 ref72/cit72 ref14/cit14 ref57/cit57 ref51/cit51 ref40/cit40 ref68/cit68 ref94/cit94 ref26/cit26 ref73/cit73 ref69/cit69 ref15/cit15 ref62/cit62 ref41/cit41 ref58/cit58 ref95/cit95 ref4/cit4 ref30/cit30 ref47/cit47 ref84/cit84 ref1/cit1 ref7/cit7 |
References_xml | – ident: ref35/cit35 doi: 10.1021/acschemneuro.2c00356 – ident: ref44/cit44 doi: 10.1016/j.jchemneu.2020.101752 – ident: ref81/cit81 doi: 10.1055/a-1349-3870 – ident: ref90/cit90 doi: 10.3390/ijms22168689 – ident: ref54/cit54 doi: 10.1002/syn.890150107 – ident: ref65/cit65 doi: 10.1038/349414a0 – ident: ref9/cit9 doi: 10.3390/ph16020160 – ident: ref25/cit25 doi: 10.1093/brain/awab152 – ident: ref15/cit15 doi: 10.1016/j.jep.2020.112769 – ident: ref4/cit4 doi: 10.1016/j.bcp.2012.08.027 – ident: ref37/cit37 doi: 10.2174/0118715249264078231214074107 – ident: ref22/cit22 doi: 10.1098/rstb.1986.0056 – ident: ref29/cit29 doi: 10.1073/pnas.042497999 – ident: ref77/cit77 doi: 10.1016/S0197-0186(96)00025-3 – ident: ref85/cit85 doi: 10.1046/j.1471-4159.2002.01000.x – ident: ref23/cit23 doi: 10.1126/science.282.5396.2028 – ident: ref83/cit83 doi: 10.1002/ps.3583 – ident: ref31/cit31 doi: 10.1016/j.addr.2013.12.001 – ident: ref8/cit8 doi: 10.1016/j.steroids.2023.109246 – ident: ref2/cit2 doi: 10.1038/35072550 – ident: ref49/cit49 doi: 10.1016/j.biopha.2018.06.002 – ident: ref69/cit69 doi: 10.1152/physrev.00026.2013 – ident: ref36/cit36 doi: 10.3390/cells12091336 – ident: ref93/cit93 doi: 10.1002/mnfr.201400014 – ident: ref76/cit76 doi: 10.1007/s10495-008-0273-y – ident: ref6/cit6 doi: 10.1016/j.ejmech.2017.09.004 – ident: ref11/cit11 doi: 10.3389/fphar.2023.1049334 – ident: ref70/cit70 doi: 10.3390/molecules14072373 – ident: ref78/cit78 doi: 10.1002/ptr.874 – ident: ref59/cit59 doi: 10.1016/0304-3940(88)90705-7 – ident: ref86/cit86 doi: 10.3389/fpsyg.2014.01093 – volume: 150 start-page: 17 issue: 1 year: 1965 ident: ref45/cit45 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(25)27139-7 – ident: ref88/cit88 doi: 10.1155/2014/768594 – ident: ref34/cit34 doi: 10.1016/j.nbd.2021.105256 – ident: ref95/cit95 doi: 10.1021/jm00027a021 – ident: ref87/cit87 doi: 10.1523/JNEUROSCI.0374-11.2011 – ident: ref56/cit56 doi: 10.1038/cr.2008.279 – ident: ref38/cit38 doi: 10.1111/bcpt.14011 – ident: ref48/cit48 doi: 10.3389/fnins.2020.00303 – ident: ref75/cit75 doi: 10.1038/sj.cdd.4402002 – ident: ref80/cit80 doi: 10.1248/cpb.50.760 – ident: ref3/cit3 doi: 10.1016/j.ejphar.2024.176819 – ident: ref14/cit14 doi: 10.1038/nchembio755 – ident: ref13/cit13 doi: 10.1248/bpb.b14-00022 – ident: ref52/cit52 doi: 10.1046/j.1471-4159.2001.00183.x – ident: ref73/cit73 doi: 10.1207/S15327914NC421_12 – ident: ref24/cit24 doi: 10.1007/s10571-006-9003-6 – ident: ref64/cit64 doi: 10.1111/j.1471-4159.1992.tb10080.x – volume: 140 start-page: 308 year: 1963 ident: ref46/cit46 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1016/S0022-3565(25)26555-7 – ident: ref40/cit40 doi: 10.3791/59243 – ident: ref55/cit55 doi: 10.1016/S0166-4328(89)80121-4 – ident: ref26/cit26 doi: 10.3390/ijms25010443 – ident: ref51/cit51 doi: 10.1056/nejm198308043090511 – ident: ref17/cit17 doi: 10.1016/j.jep.2009.08.003 – ident: ref97/cit97 doi: 10.1086/302486 – ident: ref92/cit92 doi: 10.1371/journal.pone.0238528 – ident: ref30/cit30 doi: 10.1111/j.1476-5381.2010.00725.x – ident: ref50/cit50 doi: 10.1385/JMN/31:02:127 – ident: ref68/cit68 doi: 10.1155/2021/9912436 – ident: ref47/cit47 doi: 10.1371/journal.pgen.1007106 – ident: ref89/cit89 doi: 10.1016/j.exger.2019.110653 – ident: ref41/cit41 doi: 10.1523/JNEUROSCI.2992-07.2007 – ident: ref61/cit61 doi: 10.1016/0006-291X(86)91211-8 – ident: ref67/cit67 doi: 10.1016/S0072-9752(07)83027-2 – ident: ref32/cit32 doi: 10.1096/fj.07-095398 – ident: ref57/cit57 doi: 10.1038/cdd.2017.186 – ident: ref5/cit5 doi: 10.1016/j.steroids.2011.05.012 – ident: ref96/cit96 doi: 10.1074/jbc.C500288200 – ident: ref79/cit79 doi: 10.1097/00001756-200006260-00035 – ident: ref20/cit20 doi: 10.1101/sqb.1983.048.01.049 – ident: ref33/cit33 doi: 10.3233/JPD-171258 – ident: ref62/cit62 doi: 10.3390/biomedicines11092488 – ident: ref10/cit10 doi: 10.18632/oncotarget.20497 – ident: ref19/cit19 doi: 10.3390/molecules24244599 – ident: ref42/cit42 doi: 10.1016/j.neuint.2016.01.008 – ident: ref60/cit60 doi: 10.1016/0024-3205(87)90299-2 – ident: ref7/cit7 doi: 10.1016/j.steroids.2022.109172 – ident: ref12/cit12 doi: 10.4103/1673-5374.290894 – ident: ref74/cit74 doi: 10.1124/mol.106.030015 – ident: ref91/cit91 doi: 10.3389/fgene.2012.00048 – ident: ref58/cit58 doi: 10.1016/0304-3940(87)90366-1 – ident: ref72/cit72 doi: 10.1016/S0378-8741(97)00151-7 – ident: ref53/cit53 doi: 10.1016/j.mcn.2016.06.001 – ident: ref18/cit18 doi: 10.2478/s11658-007-0015-0 – volume: 35 start-page: 297 issue: 3 year: 1997 ident: ref71/cit71 publication-title: Indian J. Exp. Biol. – ident: ref16/cit16 doi: 10.1191/0960327105ht509oa – ident: ref84/cit84 doi: 10.4103/0250-474X.95656 – ident: ref27/cit27 doi: 10.1159/000080983 – ident: ref82/cit82 doi: 10.1007/s11064-014-1443-7 – ident: ref63/cit63 doi: 10.1007/BF01271538 – ident: ref94/cit94 doi: 10.1016/j.chemosphere.2024.143303 – ident: ref39/cit39 doi: 10.3390/ijms22062929 – ident: ref66/cit66 doi: 10.1038/nrd1330 – ident: ref21/cit21 doi: 10.1016/0012-1606(77)90158-0 – ident: ref28/cit28 doi: 10.1016/j.ddtec.2012.02.002 – ident: ref98/cit98 doi: 10.1016/S0091-679X(08)61399-0 – ident: ref1/cit1 doi: 10.1093/brain/114.5.2283 – ident: ref43/cit43 doi: 10.1016/S0301-0082(01)00003-X |
SSID | ssj0069086 |
Score | 2.380019 |
Snippet | Parkinson’s disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be... Parkinson's disease is a neurodegenerative proteinopathy that primarily affects mesencephalic dopaminergic neurons. This dopaminergic depletion can be... |
SourceID | proquest pubmed crossref acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 802 |
SubjectTerms | 1-Methyl-4-phenylpyridinium - toxicity Animals Caenorhabditis elegans Cells, Cultured Dopaminergic Neurons - drug effects Mesencephalon - drug effects Mice Neuroprotective Agents - pharmacology Oxidopamine - toxicity Rats Withanolides - chemistry Withanolides - pharmacology |
Title | Neuroprotective Effect of Withaferin Derivatives toward MPP+ and 6‑OHDA Toxicity to Dopaminergic Neurons |
URI | http://dx.doi.org/10.1021/acschemneuro.4c00655 https://www.ncbi.nlm.nih.gov/pubmed/39946298 https://www.proquest.com/docview/3166763592 |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVABC databaseName: American Chemical Society Journals customDbUrl: eissn: 1948-7193 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0069086 issn: 1948-7193 databaseCode: ACS dateStart: 20100120 isFulltext: true titleUrlDefault: https://pubs.acs.org/action/showPublications?display=journals providerName: American Chemical Society |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA66Xrz4fqwvIoggktWkTbo5Lq6yCD5ARW-lSVNcZbtiu6Ke_Av-RX-Jk7T1iaiX9hKmbTKZma-Z-QahNQkWEFTDEKVij_iUStLkQpOYB1pIpiOd2Grkg0PROfP3L_jFO1D8eoLP6FakAeaZnqN3bPja-kw-jEaYaFILtlo7J5XlBaDnOjsCLm-SACKTqlTuBynWIenss0P6Icp03mZvHB1VNTtFksl1Y5Crhn78TuH4xw-ZQGNl4IlbhaZMoiGTTqHpVgqgu_eA17FLBXX_2KfRlaPsKCkcwBziguMY9xN83s0vo8TWDOI2XO8cb3iGc5d9iw-OjzdxlMZYvDw9H3XaLXzav-9qiPRhBG4DQO-5YsOuxu4RaTaDzvZ2T3c6pGzKQCImg5wkxgRBRAXcZaBErLShyoI46TrieYElOJSUJwJCT8WTOJawHExxwzUHwOfNolraT808wrD7AU2BoERr3yhLSBpZijWtYrB627KONmDOwnJTZaE7L2c0_DiRYTmRdUSqVQxvCp6OX8avVksdwoaypyRRavqDLPSoTfv1uGR1NFfowJtEiOZ8wWRz4R9vtohGme0ZbPPW-BKq5bcDswyBTK5WnPa-Am2a8Ts |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZS8NAEB60PuiL91HPFUQQ2WqOTbqPxSr1qArW4y1kNxus0lRMKuqTf8G_6C9xdpt4gYgvCYRlssdk9pvszDcAaxwtIKqGokJEDnUti9Mq8ySNmC89bstQxjobuXnsNc7dgyt2NQCsyIXBTqQoKTWH-J_sAtYWPsNRdAzLY8WVeutkgzBkyFA0Ito5Kwww-numwCO651XqI0ApMuZ-kaL3JZl-35d-AZtm09kbg4uP7ppYk9tKLxMV-fyDyfHf4xmH0RyGklpfbyZgQCWTMFVL0AXvPJF1YgJDzR_3KbgxBB45oQMaR9JnPCbdmFy2s-sw1hmEpI7XB8MinpLMxOKS5unpJgmTiHhvL68njXqNtLqPbYm4H1uQOrrrHZN62JbEvCJJp-F8b7e106B5iQYa2tzPaKyU74eWh3fuCy8SUllCu3Tc1MdzfE13yC0WewhEBYujiOOq2IIpJhm6f84MlJJuouaAoC1A3woFxVK6Smh60lATrkkRoQ3c5mXYwDkL8k8sDczpuW0FXycyyCeyDLRYzOCuz9rxR_vVYsUD_Lz0mUmYqG4vDRxLBwE7jNtlmO2rwodExHauZ_Pq_D96tgLDjVbzKDjaPz5cgBFbVxPWEW1sEUrZfU8tIcTJxLJR6Het8vmm |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEB48QHzxPuq5gggiW82xSfexWEu9CyqKLyG72WCVpsWkoj75F_yL_hJnt2mpgoi-JBDCZI_Z2W-yM98AbHK0gKgaigoROdS1LE5LzJM0Yr70uC1DGets5NMzr3blHt2wm4FSX9iIFCWl5hBfr-p2FOcMA9YuPseeNA3TY9GVevtkwzDKNAucRkX7Fz0jjD6fKfKILnqJ-ghSellzP0jRe5NMv-5NPwBOs_FUJ-G232QTb_JQ7GSiKF-_sTn-q09TMJHDUVLu6s80DKlkBmbLCbrizReyRUyAqPnzPgv3hsgjJ3ZAI0m6zMekFZPrRnYXxjqTkFTw-mTYxFOSmZhcclqv75AwiYj38fZ-XquUyWXruSER_-MbpIJue9OkIDYkMZ9I0jm4qh5c7tdoXqqBhjb3Mxor5fuh5eGd-8KLhFSW0K4dN3XyHF_THnKLxR4CUsHiKOI4M7ZgikmGbqAzDyNJK1GLQNAmoI-FgmIpXSU0TWmoidekiNAW7vECbOOYBflSSwNzim5bweBABvlAFoD2JjRod9k7fnl_ozfrAS4zfXYSJqrVSQPH0sHADuN2ARa66tCXiBjP9WxeWvpDy9ZhrF6pBieHZ8fLMG7rosI6sI2twEj22FGriHQysWZ0-hOXAPwg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuroprotective+Effect+of+Withaferin+Derivatives+toward+MPP%2B+and+6-OHDA+Toxicity+to+Dopaminergic+Neurons&rft.jtitle=ACS+chemical+neuroscience&rft.au=Parrales%2C+Valeria&rft.au=Arcile%2C+Guillaume&rft.au=Laserre%2C+Louise&rft.au=Normant%2C+S%C3%A9bastien&rft.date=2025-03-05&rft.issn=1948-7193&rft.eissn=1948-7193&rft.volume=16&rft.issue=5&rft.spage=802&rft_id=info:doi/10.1021%2Facschemneuro.4c00655&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1948-7193&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1948-7193&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1948-7193&client=summon |